Reply to Editorial Comments on "Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy".

Competing Interests: Declaration of Competing Interest Daniel E. Spratt receives research funding from the National Institutes of Health and the Prostate Cancer Foundation and personal fees from Astellas, AstraZeneca, Bayer, BlueEarth, Boston Scientific, Elekta, GT Medical Technologies Inc., Myovant, Pfizer, Janssen, Novartis, and Varian. Elisha T. Fredman serves as a consultant to Boston Scientific for the SpaceOAR product. Jonathan Shoag reports consulting fees from Fortec Medical, and grant support from the Bristol Myers Squibb Foundation. The other authors have no conflicts of interest to disclose.